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Smary In this study of 500 patients with breast carcinoma, we have prospectively assessed the role of
preoperative CA 15-3 as a marker of disea burden over a 7 year period. CA 15-3 levs at presentation
correlate with stage of diseas, tumour size, lymph node status, the presence of metastases and lymphocyte
infiltration into the tumour. CA 15-3 alone is not an independent prognostic indicator, although a serum level
of >40 U ml-' has a positive predictive value of 83% for the presence of advanced disease. We recommend
the routine use of this marker in the preoperative assement of pimary breast carcinoma.
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Breast cancer is the commonest malignancy in women. Up to
12% of women are diagnosed as having breast cancer, and
3.5% of women die from this disease. (Harris et al., 1992).
The presence and extent of lymph node involvement is cur-
rently the best established prognostic indicator. Other prog-
nostic indicators include oestrogen and progesterone receptor
status, tumour grade and growth rate, DNA ploidy and a
variety of biochemical markers of tumour invasiveness and
aggression.
Tumour markers have been widely appLied in diagnosis
and long-term follow-up of cancer patients. Recent advances
in monoclonal technology have led to the detection of
tumour-specific monoclonal antibodis which have been
marketed as potential tumour markers. These antibodies do
not detect 'breast cancer-specific antigens', but instead they
react with normal or modified tissue antigens which are
either preferentially or inappropriately expressed on malig-
nant cells. Many of these antigens are also detectable in the
serum of patients with cancer.
The carinoma-associated antigen CA 15-3 is detectable in
serum and is widely used as a tumour marker in patients
with breast carcinoma. It is an antigen defined by two mono-
clonal antibodies, DF3 (raised against a membrane enriched
fraction of a human breast carcinoma; Kufe et al., 1984) and
115D8 (raised aginst antigens of human milk fat globule
membrane; Hilkens et al., 1984, 1986). It is detectable in the
serum of breast cancer patients and has been shown to be
relatively specific for breast carcinoma (Hayes et al., 1985).
The exact role of monoclonal antibodies in the manage-
ment ofbreast carcinoma has yet to be evahlated. The aim of
this study was to define the role of CA 15-3 as a prognostic
marker in breast cancer and to compare it with sandard
predictors of outcome inchlding tumour size, lymph node
status, oestrogen receptor status, histopathological subtype of
tumour as well as the presence of lymphatic or venous
invasion.
Materal and
Since the initiation of this study in 1986, 500 breast cancer
patients have been evaluated. The cancer patients had a
mean (standard deviation) age of 57 (13.7) years. Each
patient had CA 15-3 levels determined preoperatively, post-
operatively at 3 monthly intervals for the first year, at 6
monthly intervals for the next 2 years and at yearly intervals
thereafter. Each patient also had a full dinical examination
Correspondence: HF Given
Received 16 May 1994; revised 10 October 1994; accepted 16
December 1994
performed on each of these occasions. Serum samples were
collete from 73 age-matched patients with benign breast
disease to act as controls.
At initial presentation to the breast unit, University
Colege Hospital, Galway, each patient was staged according
to the stanard UICC (1987) criteria. A thorough preoper-
ative work up was performed, which included chest radio-
graphy, liver function tests and bone scan in order to assist
in accurate patient staging.
Histological typing was performed in accordance with
standard criteria (World Health Organization, 1982). Oestro-
gen receptors were measured in tumour tissue using a stan-
dard enzyme immunoassay system (Abbott International
Diagnostics Division, Abbott Park, North Chicago, IL,
USA). The value of 10 fmol of receptor protein per mg of
cytosol protein was used as the positive/negative cut-offvalue
for oestrogen receptors. Grading was performed according to
the Bloom and Richardson (1957) system. In addition, the
presene of tumour invasion into blood vessels and lym-
phatics was noted, as was the extent of lymphocyte
infiltration into the tumour.
CA 15-3 levels were measured using a commercially avail-
able immunoradiometric assay kit (CA 15-3 solid phase
ELISA system, CIS Biointernational, ORIS Group, Gif-Sur-
Yvette, France). A sample of blood was obtained from the
patent in the morning and serum was added to a test tube
containing the antibody 115D8, coated on the enzyme-linked
immunosorbent assay (ELISA) solid phase. This was then
incubated at 3TC for 1 h. The tube was then aspirated and
washed. Following this the tracer monodonal antibody,
DF3, radiolabelled with iodine-125 was added. This was
again incubated at 3rC for 1 h, followed by a further aspira-
tion and washing. The level of bound radioactivity was
measured using a gamma-camera and kvels ofCA 15-3 were
read from a standard curve. The coefficient of variation of
the assay was ± 8%. The laboratory participates in the
United Kingdom External Quality Asssment Scheme for
Tumour Markers, and internal quality control specmens are
run within each batch of analyses. The normal level of CA
15-3 is <30Uml-'.
Results were analysed using the Mann-Whitney U-test,
the chi-square test, Fisher's exact test and regression analysis.
Signif was asumed at the P<0.05 level. Values were
analysed where applicable using two-tailed significance tests.
Re ts
A total of 500 patients with breast cancer were included in
the study; 181 (36.2%) were premenopausal and 319 (63.8%)
were post-menopausal. A total of 168 patients presented withCA 15-3 in hbeast c noma
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Table I Stage of disease and CA 15-3 levels at presentation
CA 15-3 No. (%0) with CA 15-3 Significance
CA 15-3 LUml-' (Uml-,/ CA 15-3 Significance (Lint 'i (fall in levels
Stage No. Mean (s.e.m., Median >30 U ml-' vs benign post-op post-op)
Benign 73 16.8 (0.6) 15.7 1 (1.4)
Stage
1 168 19.3 (0.8) 17.2 9 (5.4) <0.05 18.4 (0.7) NS
11 214 22.6 (0.9) 20.5 38 (17.9) <0.005 18.6 (0.6) <0.005
III 56 41.4 (6.7) 29.3 25 (45.1) <0.005 25.0 (1.8) <0.005
IV 62 91.4 (11.1) 57.5 43 (70.0) <0.005 69.8 (11.3) NS
Values given as means (s.e.m.).
Table II TNM status of tumours at presentation
CA 15-3 (L ml- ' CA 15-3 (Uml-) Number 0%0 with
TNMf status Nunber Mfean (s.e.m.) Median CA 15-3 >30 L ml-' Significance
Tumour status
TI 208 23.0 (2.3) 18.3 17 (8.2)
T2 196 25.5 (2.0) 20.0 45 (22.9) NS
T3 57 57.0 (9.2) 32.5 32 (56.1) <0.005
T4 28 49.8 (11.3) 29.4 13 (46.4) <0.005
Nodal status
NO 270 21.5 (1.2) 17.9 35 (12.9)
NI 173 34.8 (3.8) 23.6 52 (30.0) <0.005
N2 32 54.1 (13.2) 33.0 18 (56.3) <0.005
Metastases
MO 436 25.1 (1.2) 20.7 81 (18.6)
Ml 40 122.7 (14.8) 115.3 35 (87.5) <0.005
stage I disease. 214 with stage IL. 56 with stage III and 62
with stage IV disease (Table I).
At presentation the mean CA 15-3 level increased with
advancing stage of disease. There was a significant difference
in CA 15-3 levels between benign disease and stage I (P =
0.03), stage II (P<0.005), stage III (P<0.005) and stage IV
(P<0.005) disease.
A significant difference was also noted between stage I
disease and stage II (P = 0.007), stage III (P<0.005) and
stage IV (P<0.005) disease. The percentage of patients with
elevated levels of CA 15-3 also increased significantly with
more advanced stage of disease at presentation (Table I).
CA 15-3 levels were significantly correlated with tumour
size at presentation based on measurement of resected speci-
mens (r = 0.364, P<0.005). There was a significant difference
in CA 15-3 levels between Tl and T3 tumours (P< 0.005) as
well as between TI and T4 tumours (P<0.005). The
difference between TI and T2 tumours was not significant
(P = 0.06) (Table II).
There was a statistically significant positive correlation
between CA 15-3 levels and the number of involved nodes in
the group as a whole (r = 0.362, P<0.005) and the number
of involved nodes in patients in whom ten or more nodes
were examined (r = 0.497, P<0.005). A significant difference
in CA 15-3 levels was found between NO and Nl tumours
(P<0.005) and NO and N2 tumours (P<0.005). There was
no significant difference between Nl and N2 tumours (P=
0.06) (Table II).
There was a significant difference between TINOMO
tumours and TlNIMO tumours (P=0.006) as well as
between TINOMO tumours and T2NIMO tumours (P=
0.01). There was no significant difference between TINOMO
and T2NOMO (P = 0.2), T2NOMO and T2NlMO (P = 0.3) or
TINIMO and T2NIMO tumours (P=0.3).
CA 15-3 levels were highest in patients presenting with
metastatic disease. There was a significant difference in levels
between patients with metastatic disease and those without
metastatic disease at presentation (P<0.005) (Table II).
Histopathological characteristics of the tumours were
examined. There was no significant difference in CA 15-3
levels between patients with ductal carcinoma and patients
with other types of carcinoma. The percentage of patients
with an elevated CA 15-3 was increased in medullary car-
cinoma but this failed to reach statistical significance (Table
III).
Tumour grade or oestrogen receptor status (positive or
negative) did not affect the CA 15-3 level (Table III). There
was no correlation between CA 15-3 levels and oestrogen
receptor levels (r = 0.0003; P = NS). In addition. CA 15-3
levels were not related to the presence of lymphatic or venous
invasion (Table III). However, CA 15-3 levels were related to
the extent of lymphocyte infiltration, which was reported on
in 61 cases. This could be divided into none, moderate or
florid, and patients with florid lymphocyte infiltration had
significantly elevated CA 15-3 levels (Table III).
A patient presenting with a CA 15-3 > 50 U ml-' had a
91% chance of having advanced i.e. stage III or stage IV
disease (Table IV).
There was a fall in levels of CA 15-3 for all stages of
disease post-operatively; this reached significance for stage II
(P = 0.003) and stage III (P<0.002) disease, but not for the
other stages of disease (Table I).
Three hundred and eight patients presenting with stage I
or stage II disease had completed 30 months' follow-up, and
during this time 40 (12.9%) patients experienced disease
recurrence. In patients with recurrence, 12.5% (5/40) had an
elevated CA 15-3 at presentation vs 7.5% (20/268) in patients
without recurrence. However, this difference was not
significant. The difference in the mean CA 15-3 levels at
presentation between these two groups of patients also failed
to reach significance.
Discussion
CA 15-3 levels reflect tumour burden. In this study CA 15-3
levels rose significantly with advancing stage of disease as
well as with advancing tumour status, nodal status and in the
presence of metastatic disease. In addition, a significant
difference was noted between patients presenting with benign
and malignant disease, including stage I breast carcinoma.
Previous work from this unit found a significant difference
between benign and stage III and IV disease (Kerin et al.,
1989). Gion et al (1991) found no difference between benign
and stage I or II disease. The percentage of patients demon-
strating elevated CA 15-3 levels is similar to that found in
1289
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Table I Histopathological characteristics of tumours at presentation
CA 15-3 (UmI 1) CA 15-3 (Uml-1) Number (%o) with
Number Mean (s.e.m.) Median CA 15-3 >30 U ml-' Significance
ER status
Negative 97 29.4 (6.1) 22.0 24 (24.7)
Positive 235 28.7 (3.1) 21.3 40 (17.0) NS
Histology
Ductal 345 28.6 (2.3) 21.3 70 (20.2)
Medullary 5 30.7 (7.2) 34.1 3 (60.0) NS
Lobular 71 46.3 (11.4) 18.5 19 (26.7) NS
Adenocarcinoma 52 33.5 (8.5) 20.7 11 (21.1) NS
Other 6 25.3 (4.2) 21.5 1 (16.7) NS
Grade
1 (well differentiated) 44 22.5 (5.7) 18.8 11 (25.0)
2 (moderately differentiated) 72 23.3 (2.8) 21.3 9 (12.5) NS
3 (poorly differentiated) 140 30.2 (4.7) 20.1 32 (22.8) NS
Venous,lymphatic invasion
Yes 48 31.0 (6.5) 20.5 12 (25.0)
Lymphocyte infiltration
None 24 29.9 (8.3) 21.9 5 (20.8)
Moderate 21 20.7 (3.6) 19.3 5 (23.8) NS
Florid 16 51.2 (25.0) 26.9 5 (31.2) <0.05
Table IV Sensitivity, specificity and positive predictive value of
elevated CA 15-3 in the detection of advanced disease, i.e. stage III
or stage IV disease, at presentation
CA 15-3 level Positive
(Uml-,) Sensitivity Specificitn predictive value
>30 60.5 88.2 67.1
>40 46.9 %.1 82.6
>50 37.0 98.5 90.9
other studies (Robertson et al., 1990), and the statistical
significance of the results in this study may be due to the
higher numbers of patients in the current series, i.e. a type II
statistical error.
There was a significant correlation between CA 15-3 levels
and tumour size as well as the number of positive lymph
nodes and this correlation was stronger when more than ten
lymph nodes were examined. Other studies have shown no
correlation between CA 15-3, tumour size and lymph node
status (Schmict-Rhode et al., 1987; Maigre et al., 1988), but
the numbers of patients involved in these studies were
small.
Hayes et al. (1986) studied the CA 15-3 levels in 1050
healthy controls and found an elevated level (>30 U ml1)
in 1.3% of patients, which agrees with our figure of 1.4% in
benign breast disease. Elevated values have been found in
from 5% to 22% (Hayes et al., 1986) of patients with benign
breast disease, which is higher than the levels found in the
present study. The percentage of patients with a positive CA
15-3 level, i.e. the proportion of patients with a level above
the normal level of 30Uml-', incrased significantly with
advancing stage of disease as well as with tumour status,
nodal status and metastatic status. A relationship was found
between CA 15-3 positivity and tumour size and lymph node
status by Pons-Anicet et al. (1987) and Safi et al. (1987).
Krebs et al. (1988) found a relationship between CA 15-3
positivity rates and tumour size. Jager et al. (1992) showed a
higher positivity rate in node-positive than in node-negative
tumours. In this study these results were confirmed in a large
group of patients.
When stage I and II tumours were subdivided on the basis
of TN status, a difference was noted between TlNO and
T2NO and T2N1 tumours. This probably reflects the fact that
TINO lesions have the smallest tumour burden. The differ-
ence between stage I and stage II disease is small, and
differences between subdivisions are unlikely to be significant,
and this is what was observed.
Gion et al. (1991) found a statistically significant difference
in CA 15-3 levels between patients with ductal carcinoma
and medullary carcinoma. This was not evident in this study.
The highest levels of CA 15-3 were noted in lobular car-
cinoma, but no significant differences were demonstrated
between the various histological subtypes of tumour. Three
(60%) patients with medullary carcinoma had an elevated
CA 15-3 level, but no significant difference in per cent
positivity was noted, possibly because of the small number of
patients with medullary carcinoma.
CA 15-3 levels were not related to ER status, tumour
grade or the presence of venous or lymphatic invasion but
were related to the extent of inflammatory cell response. This
lack of association with other prognostic indicators is unex-
pected. A relationship between CA 15-3 levels and inflamma-
tory response has not been noted previously. It was not
dependent on the presence of ulceration and thus may reflect
an interaction between tumour and inflammatory cells result-
ing in increased release of this glycoprotein into the circula-
tion.
CA 15-3 levels dropped post-operatively in all stages of
disease. The fall was significant for stage II and stage III
disease. This reflects a reduction in tumour burden. In stage I
disease the initial tumour burden is small, and in stage IV
disease much of the initial tumour burden is inaccessible to
the surgeon.
CA 15-3 levels in stage I and II disease tended to be higher
at presentation in patients who developed recurrence within
the first 30 months of follow-up, however the difference was
not significant.
CA 15-3 clearly correlates with disease burden. This
confirms the work of Gion et al. (1991). This study has failed
to demonstrate that CA 15-3 has prognostic significance at
presentation in early disease, however it does provide inform-
ation on tumour burden as patients with levels of greater
than 40 U ml-' have an 83% chance of having at least stage
III disease. We recommend the routine use of this valuable
tumour marker in the preoperative assessment of patients
who present with primary breast carcinoma.CA 15-3 in breh casinona
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